Becton, Dickinson and Company
NYSE:BDXMedical - Instruments & Supplies
+$2.36 today
- Market cap
- $58.86B
- Beta
- 0.28
- P/E (TTM)
- 35.5
- EPS (TTM)
- $4.06
- Dividend yield
- 2.60%
Volume 1.32M
Average 2.76M
BDX Interest Expense
Cost of servicing the company's debt during the period.
Becton, Dickinson and CompanyNYSE: BDX
Interest Expense · Q4 FY2026 · quarter ended Sep 2026
Interest expense declines year over year
Q4 FY2026 interest expense of $130M fell 16.1% year over year, behind the -15.5% change in trailing-twelve-month interest expense. Sequentially, it fell 1.5% from the prior quarter. Over 3 fiscal years it compounded at +7.7% a year.
Context
- Interest expense amounted to 2.9% of revenue in FY2026, unchanged from a year earlier.
- Interest expense increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -16.1% toward the trailing-twelve-month pace of -15.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2026
- 564M USD
- Year-over-year change
- -8.0%
- 4-year CAGR
- +9.1%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | 564M | -8.0% |
| FY2025 | 2025-09-30 | 613M | +16.1% |
| FY2024 | 2024-09-30 | 528M | +16.8% |
| FY2023 | 2023-09-30 | 452M | +13.6% |
| FY2022 | 2022-09-30 | 398M | — |
Interest Expense vs competitors
How BDX compares with its peers on the latest reported figures
- BDX's LTM Sep 2026 interest expense of $518M is the 3rd highest of the 11 companies compared; the peer median is $109.42M.
- Its year-over-year change of -15.5% is the 6th highest of 11, against a peer median of -14.1%.
- Interest expense amounts to 2.6% of revenue for BDX, versus a peer median of 2.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $890M | +97.3% | +2.7% | 1.8% | |
| LTM Jul 2026 | $725M | -1.8% | +4.0% | 1.9% | |
| LTM Sep 2026 | $518M | -15.5% | +7.7% | 2.6% | |
| LTM Jun 2026 | $292M | -17.5% | -11.1% | 2.5% | |
| LTM Jun 2026 | $266M | -36.8% | — | 3.2% | |
| LTM Jun 2026 | $119.43M | +49.4% | +22.7% | 4.6% | |
| LTM Mar 2026 | $99.4M | -10.8% | +32.4% | 9.5% | |
| LTM Jun 2026 | $82.95M | -21.4% | +14.2% | 3.8% | |
| LTM Sep 2026 | $17.68M | -37.1% | +61.0% | 1.1% | |
| LTM Mar 2026 | $660K | +28.9% | +57.9% | 0.7% | |
| LTM Jun 2026 | $100K | -91.7% | -57.1% | 0.0% | |
| Peer median (excluding BDX) | $109.42M | -14.1% | +14.2% | 2.2% | |
Competitors are the stored peer set for BDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Revenue | 18.87B | 19.37B | 20.18B | 21.84B | 19.46B |
| Cost of Revenue | 10.39B | 11.2B | 11.05B | 11.92B | 10.24B |
| Gross Profit | 8.48B | 8.17B | 9.13B | 9.92B | 9.21B |
| Gross Margin | 44.9% | 42.2% | 45.2% | 45.4% | 47.4% |
| Research & Development | 1.26B | 1.24B | 1.19B | 1.26B | 988M |
| Selling, General & Admin | 4.71B | 4.72B | 4.86B | 5.28B | 4.97B |
| Operating Expenses | 6.2B | 6.06B | 6.73B | 7.35B | 6.96B |
| Depreciation & Amortization | 2.23B | 2.29B | 2.29B | 2.46B | 2.24B |
| EBITDA | 4.41B | 4.4B | 4.82B | 4.96B | 4.61B |
| EBITDA Margin | 23.4% | 22.7% | 23.9% | 22.7% | 23.7% |
| Operating Income | 2.28B | 2.11B | 2.4B | 2.58B | 2.26B |
| Operating Margin | 12.1% | 10.9% | 11.9% | 11.8% | 11.6% |
| Interest Income | 16M | 49M | 163M | 38M | 27M |
| Interest Expense | 398M | 452M | 528M | 613M | 564M |
| Other Income / Expenses | (499M) | (449M) | (392M) | (696M) | (451M) |
| Income Before Tax | 1.78B | 1.66B | 2.01B | 1.88B | 1.81B |
| Pre-Tax Margin | 9.4% | 8.6% | 9.9% | 8.6% | 9.3% |
| Income Tax Expense | 148M | 132M | 300M | 204M | 388M |
| Net Income | 1.78B | 1.48B | 1.71B | 1.68B | 1.15B |
| Net Margin | 9.4% | 7.7% | 8.4% | 7.7% | 5.9% |
| EPS (Basic) | 5.93 | 4.97 | 5.88 | 5.84 | 4.11 |
| EPS (Diluted) | 5.88 | 4.94 | 5.86 | 5.83 | 4.09 |
| Weighted Avg Shares | 285.01M | 286.28M | 289.76M | 286.61M | 278.49M |
| Weighted Avg Shares (Diluted) | 287.36M | 288.39M | 291.01M | 287.12M | 279.94M |
Becton, Dickinson and Company
NYSE:BDX
Intrinsic Alpha fair value
Locked
Current Price
$216.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.